Develop formal scientific policies for the conduct of pharmacoeconomic and outcomes research, 2. The meeting agenda included updates on recent progress from the task forces, committees and SIGs. New developments raised included the debate over Medicare drug coverage in the US, the continued development of pharmacoeconomic guidelines in Europe and the US, and the concern over rising prescription drug costs. Communicating the results and methods of our work in terms that are accessible and meaningful to other health care professionals and health care decision makers, and 2. assuring the information we generate is at the level of study design and analysis rigor needed to make decisions about reimbursement coverage and utilization priorities for prescription drugs and other health care technologies. In my mind, these are simultaneously immediate and evolutionary needs.
Individual researchers can take responsibility for the immediate needs.
Happy autumn to all.